Trexquant Investment’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.7M | Buy |
+20,543
| New | +$6.7M | 0.08% | 412 |
|
|
2025
Q1 | – | Sell |
-44,024
| Closed | -$10.4M | – | 1525 |
|
|
2024
Q4 | $10.4M | Sell |
44,024
-46,719
| -51% | -$11M | 0.12% | 251 |
|
|
2024
Q3 | $25M | Buy |
90,743
+52,880
| +140% | +$14.5M | 0.32% | 54 |
|
|
2024
Q2 | $9.2M | Sell |
37,863
-59,112
| -61% | -$14.4M | 0.14% | 211 |
|
|
2024
Q1 | $14.5M | Buy |
96,975
+45,578
| +89% | +$6.81M | 0.29% | 54 |
|
|
2023
Q4 | $9.84M | Buy |
51,397
+40,376
| +366% | +$7.73M | 0.22% | 109 |
|
|
2023
Q3 | $1.95M | Buy |
+11,021
| New | +$1.95M | 0.05% | 496 |
|
|
2023
Q1 | – | Sell |
-43,673
| Closed | -$10.4M | – | 1409 |
|
|
2022
Q4 | $10.4M | Buy |
43,673
+561
| +1% | +$133K | 0.29% | 81 |
|
|
2022
Q3 | $8.63M | Buy |
+43,112
| New | +$8.63M | 0.3% | 73 |
|
|
2022
Q2 | – | Sell |
-21,496
| Closed | -$3.51M | – | 1487 |
|
|
2022
Q1 | $3.51M | Buy |
+21,496
| New | +$3.51M | 0.16% | 152 |
|
|
2021
Q1 | – | Sell |
-6,393
| Closed | -$831K | – | 1092 |
|
|
2020
Q4 | $831K | Buy |
+6,393
| New | +$831K | 0.09% | 301 |
|
|
2020
Q2 | – | Sell |
-16,471
| Closed | -$1.79M | – | 1146 |
|
|
2020
Q1 | $1.79M | Buy |
16,471
+10,522
| +177% | +$1.15M | 0.13% | 238 |
|
|
2019
Q4 | $685K | Buy |
5,949
+214
| +4% | +$24.6K | 0.04% | 469 |
|
|
2019
Q3 | $461K | Sell |
5,735
-8,858
| -61% | -$712K | 0.04% | 472 |
|
|
2019
Q2 | $1.06M | Buy |
14,593
+4,513
| +45% | +$328K | 0.1% | 297 |
|
|
2019
Q1 | $942K | Buy |
+10,080
| New | +$942K | 0.07% | 415 |
|
|
2018
Q1 | – | Sell |
-3,021
| Closed | -$384K | – | 1043 |
|
|
2017
Q4 | $384K | Buy |
+3,021
| New | +$384K | 0.04% | 625 |
|
|
2015
Q4 | – | Sell |
-27,859
| Closed | -$2.24M | – | 985 |
|
|
2015
Q3 | $2.24M | Buy |
+27,859
| New | +$2.24M | 0.19% | 126 |
|